Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Global Phase 2b, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy - FORTITUDE-HCM

NCT07023614 is registered in ClinicalTrials.gov with Imbria Pharmaceuticals, Inc. as lead sponsor.

NCT NCT07023614
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07023614 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Global Phase 2b, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy - FORTITUDE-HCM
Lead sponsor
Imbria Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
October 6, 2025
Completion date
December 31, 2026
Enrollment
165 (estimated)
Sites
67

Conditions

As the registry lists them; a condition with its own page is linked.

non-obstructive hypertrophic cardiomyopathy